AZD4144 clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2023
How each study uses AZD4144 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2023 (1)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses AZD4144 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study of Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]AZD4144CompletedPhase 1AstraZenecaNCT07518459Written as [14C]AZD4144 Solution for Infusion
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy ParticipantsCompletedPhase 1AstraZenecaNCT06491550Written as AZD4144- Part A
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy ParticipantsCompletedPhase 1AstraZenecaNCT06122714Written as AZD4144 Part A